Fosun Pharmaceutical announced that the holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. received approval from the State Drug Administration to conduct phase II/III adaptive seamless design clinical trials for the treatment of non-segmental vitiligo; the company plans to conduct related clinical research in China after conditions are met.

Zhitongcaijing · 1d ago
Fosun Pharmaceutical announced that the holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. received approval from the State Drug Administration to conduct phase II/III adaptive seamless design clinical trials for the treatment of non-segmental vitiligo; the company plans to conduct related clinical research in China after conditions are met.